PCN21 Comparative Effectiveness and Cost-Effectiveness Assessment of Erlotinib Versus Gefitinib in First-Line Treatment of EGFR Activating Mutation Positive Non-Small Cell Lung Cancer for Hong Kong

Abstract

of novel cancer drugs approved over the past 11 years are used with a curative intent or provide a survival benefit in the palliative care setting. However, the monthly cost for agents not providing these benefits was higher, indicating a disconnect between efficacy and cost.